Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co Days Payable Chart
Chunghwa Chemical Synthesis & Biotech Co Annual Data
TPE:1762 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chunghwa Chemical Synthesis & Biotech Co Days Payable vs Biotechnology Industry
Chunghwa Chemical Synthesis & Biotech Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a Days Payable of 22.59 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. This is 29% below median its historical median of 31.94. Over the past decade, Chunghwa Chemical Synthesis & Biotech Co's Days Payable has ranged from 15.50 to 37.00. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #646 out of 706 companies in the Biotechnology industry, placing it in the top 91.5%.
Is Chunghwa Chemical Synthesis & Biotech Co's Days Payable too high?
Chunghwa Chemical Synthesis & Biotech Co's current Days Payable of 22.59 is 29% below median its 10-year median of 31.94. Over the past 10 years, this metric has ranged from a low of 15.50 to a high of 37.00. The Biotechnology industry median Days Payable is 110.85. Chunghwa Chemical Synthesis & Biotech Co's value of 22.59 is 79.6% below this industry median. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #646 out of 706 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #646 out of 706 companies for Days Payable. This places Chunghwa Chemical Synthesis & Biotech Co in the lower half of its industry. The industry median Days Payable is 110.85. Chunghwa Chemical Synthesis & Biotech Co's value of 22.59 is 79.6% below this benchmark. Historically, Chunghwa Chemical Synthesis & Biotech Co's own Days Payable has ranged from 15.50 to 37.00 over the past decade. While the company's 10-year median is 31.94 vs. the industry median of 110.85, Chunghwa Chemical Synthesis & Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.85, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chunghwa Chemical Synthesis & Biotech Co's current Days Payable of 22.59 is 79.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. For the Biotechnology industry, the median Days Payable is 110.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chunghwa Chemical Synthesis & Biotech Co's current Days Payable is 22.59, which is 29% below median its own 10-year median of 31.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Fairly Valued. The stock's GF Value™ is NT$36.42, compared to a current price of NT$35.95 — trading 1.3% below its estimated fair value. The current Days Payable is 22.59, which is 29% below median its 10-year median of 31.94 and 79.6% below the Biotechnology industry median of 110.85. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current Days Payable is 22.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be undervalued.
The current stock price of NT$35.95 is trading 1.3% below its estimated GF Value™ of NT$36.42.
GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1762:
Days Payable: 22.59 (29% below median its 10-year median of 31.94)
GF Value™: NT$36.42 vs. price of NT$35.95 (1.3% below fair value)
Industry Position: 79.6% below the Biotechnology median (#646 of 706)
No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
66GF Score
Get the complete analysis for TPE:1762
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1762 has been successfully added to your 
